Related Experiment Video
Updated: May 19, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
Multiple cancer testis antigens function to support tumor cell mitotic fidelity
Kathryn M Cappell1, Rebecca Sinnott, Patrick Taus
1Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Abstract:
While the expression of genes that are normally involved in spermatogenesis is frequently detected in tumors, the extent to which these gene products are required for neoplastic behaviors is unclear. To begin to address their functional relevance to tumorigenesis, we identified a cohort of proteins which display synthetic lethality with paclitaxel in non-small-cell lung cancer and whose expression is biased toward testes and tumors. Remarkably, these testis proteins, FMR1NB, NXF2, MAGEA5, FSIP1, and STARD6, are required for accurate chromosome segregation in tumor cells. Their individual depletion enhances the generation of multipolar spindles, increases mitotic transit time, and induces micronucleation in response to an otherwise innocuous dose of paclitaxel. The underlying basis for abnormal mitosis is an alteration in microtubule function, as their depletion increases microtubule cytaster formation and disrupts microtubule stability. Given these observations, we hypothesize that reactivated testis proteins may represent unique tumor cell vulnerabilities which, if targeted, could enhance responsiveness to antimitotic therapy. Indeed, we demonstrate that combining paclitaxel with a small-molecule inhibitor of the gametogenic and tumor cell mitotic protein TACC3 leads to enhanced centrosomal abnormalities, activation of death programs, and loss of anchorage-independent growth.
Insights
Reactivated testis proteins are essential for chromosome segregation in non-small-cell lung cancer cells. Targeting these proteins, alongside paclitaxel, enhances anti-cancer effects by disrupting mitosis and promoting cell death.
Area of Science:
- Oncology
- Cell Biology
- Genetics
Background:
- Spermatogenesis gene expression is common in tumors, but their role in cancer is unclear.
- Identifying proteins with synthetic lethality to paclitaxel in non-small-cell lung cancer (NSCLC) is crucial.
Purpose of the Study:
- To investigate the functional relevance of testis-biased proteins in tumorigenesis.
- To explore targeting these proteins to enhance anti-mitotic therapy efficacy.
Main Methods:
- Identified testis proteins (FMR1NB, NXF2, MAGEA5, FSIP1, STARD6) exhibiting synthetic lethality with paclitaxel in NSCLC.
- Assessed the impact of depleting these proteins on chromosome segregation, mitosis, and microtubule stability.
- Investigated the combined effect of paclitaxel and a TACC3 inhibitor.
Main Results:
- Depletion of identified testis proteins disrupted chromosome segregation, increased mitotic errors (multipolar spindles, micronucleation), and altered microtubule function.
- These proteins are required for accurate chromosome segregation in tumor cells.
- Combining paclitaxel with a TACC3 inhibitor induced centrosomal abnormalities, cell death, and reduced anchorage-independent growth.
Conclusions:
- Reactivated testis proteins represent potential vulnerabilities in tumor cells.
- Targeting these proteins can enhance the efficacy of anti-mitotic therapies like paclitaxel in NSCLC.
Related Concept Videos
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation
Mitogens and the Cell Cycle
Cancers Originate from Somatic Mutations in a Single Cell
Tumor Immunotherapy

